![Bruce Maclachlan BSc (Hons), PhD](https://profiles-cardiff.imgix.net/attachments/7248?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Bruce Maclachlan
(e/fe)
BSc (Hons), PhD
Timau a rolau for Bruce Maclachlan
Cymrawd Ymchwil Iechyd HCRW
Trosolwg
Mae fy ymchwil yn defnyddio technegau strwythurol, bioffisegol a chellog i gael mewnwelediad i swyddogaeth imiwnedd. Mae fy niddordeb yn y digwyddiadau cydnabod rhwng celloedd imiwnedd a'u targedau. Mae gen i ddiddordeb penodol mewn adnabod celloedd T o antigenau a gyflwynir ar foleciwlau cymhleth histocompatibility mawr (MHC). Nod fy ngwaith yw deall rheolau moleciwlaidd y system hon er mwyn manteisio ar ein dealltwriaeth i gynhyrchu therapïau imiwnedd gwell.
Cyhoeddiad
2026
- Saud, Z. et al. 2026. Discovery of a fungal Tc toxin complex and functional mycoserpin through a novel two-by-two comparative genomics approach. Frontiers in Cellular and Infection Microbiology 16 1800461. (10.3389/fcimb.2026.1800461)
2024
- Pymm, P. et al., 2024. The structural basis for recognition of human leukocyte antigen class I molecules by the Pan-HLA antibody w6/32. The Journal of Immunology 213 (6), pp.876-885. (10.4049/jimmunol.2400328)
- MacLachlan, B. et al. 2024. Structure of the murine CD94–NKG2A receptor in complex with Qa-1b presenting an MHC-I leader peptide. The FEBS Journal 291 (7), pp.1530-1544. (10.1111/febs.17050)
- Hulin-Curtis, S. et al., 2024. A targeted single mutation in influenza A virus universal epitope transforms immunogenicity and protective immunity via CD4+ T cell activation. Cell Reports 43 (6) 114259. (10.1016/j.celrep.2024.114259)
2023
- Chen, Y. et al. 2023. Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4+ T cell immunity. Cell Reports 42 (8) 112827. (10.1016/j.celrep.2023.112827)
2021
- Burnell, S. E. A. et al. 2021. Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. Immunotherapy Advances 2 (1) ltab025. (10.1093/immadv/ltab025)
- MacLachlan, B. J. et al. 2021. Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. European Journal of Immunology 51 (2), pp.331-341. (10.1002/eji.202048753)
2020
- Greenshields-Watson, A. et al. 2020. CD4 + T cells recognize conserved influenza A epitopes through shared patterns of V-Gene usage and complementary biochemical features. Cell Reports 32 (2) 107885. (10.1016/j.celrep.2020.107885)
2019
- Besneux, M. et al., 2019. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunology, Immunotherapy 68 , pp.247-256. (10.1007/s00262-018-2266-1)
2018
- Holland, C. J. et al. 2018. In silico and structural analyses demonstrate that intrinsic protein motions guide T cell receptor complementarity determining region loop flexibility. Frontiers in Immunology 9 674. (10.3389/fimmu.2018.00674)
2017
- MacLachlan, B. J. et al. 2017. Using X-ray crystallography, biophysics, and functional assays to determine the mechanisms governing T-cell receptor recognition of cancer antigens. Journal of Visualized Experiments (120) e54991. (10.3791/54991)
2016
- MacLachlan, B. J. 2016. Molecular characterisation of CD4+ T cell responses to tumour antigens. PhD Thesis , Cardiff University.
Erthyglau
- Saud, Z. et al. 2026. Discovery of a fungal Tc toxin complex and functional mycoserpin through a novel two-by-two comparative genomics approach. Frontiers in Cellular and Infection Microbiology 16 1800461. (10.3389/fcimb.2026.1800461)
- Pymm, P. et al., 2024. The structural basis for recognition of human leukocyte antigen class I molecules by the Pan-HLA antibody w6/32. The Journal of Immunology 213 (6), pp.876-885. (10.4049/jimmunol.2400328)
- MacLachlan, B. et al. 2024. Structure of the murine CD94–NKG2A receptor in complex with Qa-1b presenting an MHC-I leader peptide. The FEBS Journal 291 (7), pp.1530-1544. (10.1111/febs.17050)
- Hulin-Curtis, S. et al., 2024. A targeted single mutation in influenza A virus universal epitope transforms immunogenicity and protective immunity via CD4+ T cell activation. Cell Reports 43 (6) 114259. (10.1016/j.celrep.2024.114259)
- Chen, Y. et al. 2023. Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4+ T cell immunity. Cell Reports 42 (8) 112827. (10.1016/j.celrep.2023.112827)
- Burnell, S. E. A. et al. 2021. Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. Immunotherapy Advances 2 (1) ltab025. (10.1093/immadv/ltab025)
- MacLachlan, B. J. et al. 2021. Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. European Journal of Immunology 51 (2), pp.331-341. (10.1002/eji.202048753)
- Greenshields-Watson, A. et al. 2020. CD4 + T cells recognize conserved influenza A epitopes through shared patterns of V-Gene usage and complementary biochemical features. Cell Reports 32 (2) 107885. (10.1016/j.celrep.2020.107885)
- Besneux, M. et al., 2019. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunology, Immunotherapy 68 , pp.247-256. (10.1007/s00262-018-2266-1)
- Holland, C. J. et al. 2018. In silico and structural analyses demonstrate that intrinsic protein motions guide T cell receptor complementarity determining region loop flexibility. Frontiers in Immunology 9 674. (10.3389/fimmu.2018.00674)
- MacLachlan, B. J. et al. 2017. Using X-ray crystallography, biophysics, and functional assays to determine the mechanisms governing T-cell receptor recognition of cancer antigens. Journal of Visualized Experiments (120) e54991. (10.3791/54991)
Gosodiad
- MacLachlan, B. J. 2016. Molecular characterisation of CD4+ T cell responses to tumour antigens. PhD Thesis , Cardiff University.
Ymchwil
Mae fy ymchwil yn canolbwyntio ar sut mae'r system imiwnedd yn cydnabod canser gyda'r nod o harneisio'r wybodaeth hon i ddylunio brechlynnau canser gwell. Rwyf wedi defnyddio technegau bioleg strwythurol a moleciwlaidd i ddeall digwyddiadau pwysig o ran adnabod imiwnedd rhwng celloedd imiwnedd a antigenau targed – sy'n tynnu sylw at bresenoldeb canser neu haint firaol i'r system imiwnedd.
Fy nodau ymchwil presennol yw disgrifio natur antigenau tiwmor sy'n cael eu cyflwyno i gelloedd CD4+ T i'w hadnabod a defnyddio dulliau strwythurol dan arweiniad i wneud i gelloedd T adnabod y gwrthfiotigau tiwmor hyn yn fwy effeithiol.
Bywgraffiad
Astudiais BSc Biocemeg (Anrh) yng Ngholeg Imperial Llundain (2012). Dyfarnwyd PhD mewn Bioleg Canser i mi o Brifysgol Caerdydd yn 2017 lle astudiais gelloedd T 'helpwr' CD4+ mewn canser colorectal dan oruchwyliaeth Dr David Cole a'r Athro Andrew Godkin. Yn 2018, treuliais amser fel ymchwilydd ôl-ddoethurol ym Mhrifysgol Monash (Awstralia) yn labordy yr Athro Jamie Rossjohn, gan ymchwilio i dderbynyddion celloedd NK. Yn 2022, dyfarnwyd Cymrodoriaeth Ymchwil Iechyd i mi gan Ymchwil Iechyd a Gofal Cymru i astudio system gyflwyno antigen dosbarth II HLA.
Contact Details
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Ystafell 3F08, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
Themâu ymchwil
Arbenigeddau
- Bioleg strwythurol
- Imiwnoleg
- Cemeg protein
- Imiwnoleg canser
- Imiwnedd celloedd T